PMID- 25512818
OWN - NLM
STAT- MEDLINE
DCOM- 20150811
LR  - 20181113
IS  - 2005-6745 (Electronic)
IS  - 2005-6737 (Print)
IS  - 2005-6737 (Linking)
VI  - 55
IP  - 12
DP  - 2014 Dec
TI  - Efficacy, tolerability, and safety of oxybutynin chloride in pediatric neurogenic 
      bladder with spinal dysraphism: a retrospective, multicenter, observational 
      study.
PG  - 828-33
LID - 10.4111/kju.2014.55.12.828 [doi]
AB  - PURPOSE: Anticholinergics are a key element in treating neurogenic detrusor 
      overactivity, but only limited data are available in the pediatric population, 
      thus limiting the application to children even for oxybutynin chloride (OC), a 
      prototype drug. This retrospective study was designed to provide data regarding 
      the efficacy, tolerability, and safety of OC in the pediatric population (0-15 
      years old) with spinal dysraphism (SD). MATERIALS AND METHODS: Records relevant 
      to OC use for neurogenic bladder were gathered and scrutinized from four 
      specialized clinics for pediatric urology. The primary efficacy outcomes were 
      maximal cystometric capacity (MCC) and end filling pressure (EFP). Data on 
      tolerability, compliance, and adverse events (AEs) were also analyzed. RESULTS: 
      Of the 121 patient records analyzed, 41 patients (34%) received OC at less than 5 
      years of age. The range of prescribed doses varied from 3 to 24 mg/d. The median 
      treatment duration was 19 months (range, 0.3-111 months). Significant improvement 
      of both primary efficacy outcomes was noted following OC treatment. MCC increased 
      about 8% even after adjustment for age-related increases in MCC. Likewise, mean 
      EFP was reduced from 33 to 21 cm H2O. More than 80% of patients showed compliance 
      above 70%, and approximately 50% of patients used OC for more than 1 year. No 
      serious AEs were reported; constipation and facial flushing consisted of the 
      major AEs. CONCLUSIONS: OC is safe and efficacious in treating pediatric 
      neurogenic bladder associated with SD. The drug is also tolerable and the safety 
      profile suggests that adjustment of dosage for age may not be strictly observed.
FAU - Lee, Jung Hoon
AU  - Lee JH
AD  - Department of Urology, Seoul National University College of Medicine, Seoul, 
      Korea.
FAU - Kim, Kyoung Rok
AU  - Kim KR
AD  - Department of Urology, Seoul National University College of Medicine, Seoul, 
      Korea.
FAU - Lee, Yong Seung
AU  - Lee YS
AD  - Department of Urology, Urological Science Institute, Yonsei University College of 
      Medicine, Seoul, Korea.
FAU - Han, Sang Won
AU  - Han SW
AD  - Department of Urology, Urological Science Institute, Yonsei University College of 
      Medicine, Seoul, Korea.
FAU - Kim, Kun Suk
AU  - Kim KS
AD  - Department of Urology, Asan Medical Center, University of Ulsan College of 
      Medicine, Seoul, Korea.
FAU - Song, Sang Hoon
AU  - Song SH
AD  - Department of Urology, Asan Medical Center, University of Ulsan College of 
      Medicine, Seoul, Korea.
FAU - Baek, Minki
AU  - Baek M
AD  - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of 
      Medicine, Seoul, Korea.
FAU - Park, Kwanjin
AU  - Park K
AD  - Division of Pediatric Urology, Department of Urology, Seoul National University 
      Childrens' Hospital, Seoul National University College of Medicine, Seoul, Korea.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20141128
PL  - Korea (South)
TA  - Korean J Urol
JT  - Korean journal of urology
JID - 101499376
RN  - 0 (Mandelic Acids)
RN  - 0 (Muscarinic Antagonists)
RN  - 0 (Urological Agents)
RN  - K9P6MC7092 (oxybutynin)
SB  - IM
MH  - Adolescent
MH  - Child
MH  - Child, Preschool
MH  - Drug Evaluation/methods
MH  - Female
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Male
MH  - Mandelic Acids/adverse effects/*therapeutic use
MH  - Muscarinic Antagonists/adverse effects/*therapeutic use
MH  - Retrospective Studies
MH  - Spinal Dysraphism/*complications
MH  - Treatment Outcome
MH  - Urinary Bladder, Neurogenic/*drug therapy/etiology/physiopathology
MH  - Urological Agents/adverse effects/*therapeutic use
PMC - PMC4265718
OTO - NOTNLM
OT  - Child
OT  - Neurogenic urinary bladder
OT  - Oxybutynin
COIS- The authors have nothing to disclose.
EDAT- 2014/12/17 06:00
MHDA- 2015/08/12 06:00
PMCR- 2014/12/01
CRDT- 2014/12/17 06:00
PHST- 2014/08/29 00:00 [received]
PHST- 2014/10/15 00:00 [accepted]
PHST- 2014/12/17 06:00 [entrez]
PHST- 2014/12/17 06:00 [pubmed]
PHST- 2015/08/12 06:00 [medline]
PHST- 2014/12/01 00:00 [pmc-release]
AID - 10.4111/kju.2014.55.12.828 [doi]
PST - ppublish
SO  - Korean J Urol. 2014 Dec;55(12):828-33. doi: 10.4111/kju.2014.55.12.828. Epub 2014 
      Nov 28.